S-triazolyl α-mercaptoacetanilides as inhibitors of...

Details S-triazolyl α-mercaptoacetanilides as inhibitors of... S-triazolyl α-mercaptoacetanilides as inhibitors of...

2011-05-24

2011-05-24

Shameem, Golam M (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C548S262200, C548S263200, C548S263800, C514S383000

Reexamination Certificate

active

07947721

ABSTRACT:
A series of S-triazolyl α-mercaptoacetanilides having general structure (1) are provided, where Q is CO2H, CONR2, SO3H, or SO2NR2. The compounds inhibit several variants of the reverse transcriptase of HIV, and are useful in the treatment of HIV infections.

REFERENCES:
patent: 5939462 (1999-08-01), Connell et al.
patent: 6197779 (2001-03-01), Andries et al.
patent: 6245817 (2001-06-01), Connell et al.
patent: 6414147 (2002-07-01), Currie et al.
patent: 7435752 (2008-10-01), Girardet
patent: 7642277 (2010-01-01), Simoneau et al.
patent: 7683087 (2010-03-01), Girardet et al.
patent: 2002/0026186 (2002-02-01), Woloszko et al.
patent: 2003/0027433 (2003-02-01), Faur et al.
patent: 2005/0054639 (2005-03-01), Simoneau
patent: 2006/0135556 (2006-06-01), Girardet et al.
patent: 2006/0270725 (2006-11-01), Girardet et al.
patent: 2008/0249131 (2008-10-01), Girardet et al.
patent: 2008/0319201 (2008-12-01), Girardet
patent: 2009/0197825 (2009-08-01), Quart et al.
patent: 2010/0069645 (2010-03-01), Girardet
patent: 2010/0081827 (2010-04-01), Girardet
patent: 2010/0137590 (2010-06-01), Girardet
patent: 1050531 (1979-03-01), None
patent: 1545483 (2005-06-01), None
patent: 1789039 (2007-05-01), None
patent: 2135608 (2009-12-01), None
patent: 7215940 (1995-08-01), None
patent: WO 00/27850 (2000-05-01), None
patent: WO 02/070470 (2002-09-01), None
patent: WO 03/016306 (2003-02-01), None
patent: WO 03/097047 (2003-11-01), None
patent: WO-2004-030611 (2004-04-01), None
patent: WO 2004/030611 (2004-04-01), None
patent: WO-2004-050643 (2004-06-01), None
patent: WO 2004/050643 (2004-06-01), None
patent: WO 2004/069812 (2004-08-01), None
patent: WO 2005/028479 (2005-03-01), None
patent: WO-2007-050087 (2007-05-01), None
patent: WO-2010-048592 (2010-04-01), None
patent: WO-2010-048593 (2010-04-01), None
Modi et al., “Synthesis of substituted 1,2 arylhydrazones of 4-ary1-4H-1,2,4-triazoly1-3-thioacetic acid hydrazides,” J. Indian Chem. Soc. 54:1087-1089 (1977).
Modi et al., “Synthesis of S-(4-aryl-4H-1,2,4-triazol-3y1)2-mercaptomethyl benuimidazoles,” J. Indian Chem. Soc. 54:741-742 (1977).
PCT/US05/39294 Search Report dated Jun. 16, 2006.
PCT/US05/30259 Search Report dated May 30, 2006.
EP 05790722 Search Report dated Jun. 26, 2009.
EP 09170772 Search Report dated Oct. 14, 2009.
U.S. Appl. No. 12/618,638, filed Nov. 13, 2009.
U.S. Appl. No. 12/633,638, filed Dec. 8, 2009.
Ainsworth, C. 1,2,4-Triazole. Org. Syn., Coll. 1973; vol. V: 1070. (4 pages).
Badger, et al. Azaindoles. III. The synthesis of pyrazolo[3,4-b]pyridines and pyrazolo-[3,4-d]primidines. Aust. J. Chem. 1965; 18(8): 1267-71.
Berge, et al. Pharmaceutical salts. J. Pharm. Sci. 1977; 66(1): 1-19.
Bontems, et al. Guanosine analogues: Synthesis of nucleosides of certain 3-substituted 6-aminopyrazolo[3,4-d]pyrimidin-4(5H)-ones as potential immunotherapeutic agents. J. Med. Chem. 1990; 33(8): 2174-8.
Connor, et al. Characterization of the functional properties of env genes from long-term survivors of human immunodeficiency virus type 1 infection. J. Virol. 1996; 70(8): 5306-11.
Harrington, et al. Direct detection of infectious HIV-1 in blood using a centrifugation-indicator cell assay. J. Virol. Methods. 2000; 88(1): 111-5.
Ibata, et al. Formation and reaction of oxazoles: Synthesis of N-substituted 2-(aminomethyl)oxazoles. Bull. Chem. Soc. Jpn. 1989; 62: 618-20.
Ibata, et al. The acid catalyzed decomposition of diazo compounds. I. Synthesis of oxazoles in the BF3 catalyzed reaction of diazo carbonyl compounds with nitriles. Bull. Chem. Soc. Jpn. 1979; 52: 3597-600.
Larsen, et al. Prodrug forms for the sulfonamide group. I: Evaluation of N-acyl derivatives, N-sulfonylamidines, N-sulfonylfilimines and sulfonylureas as possible prodrug derivatives. Int. J. Pharm. 1987; 37(1-2): 87-95.
Lewis, et al. Pyrazolopyrimidine nucleosides. 13. Synthesis of the novel C-nucleoside 5-amino-3-(βD-ribofuranosyl)pyrazolo[4,3-d]pyrimidin-7-one, a guanosine analogue related to the nucleoside antibiotic formycin B. J. Am. Chem. Soc. 1988; 104: 1073-7.
Liu, et al. An improved synthesis of 9-deazaguanine. Synthetic Communications. 2002; 32(24): 3797-802. (edited by Klaus Kielich).
Lopes, et al. Acyloxymethyl as a drug protecting group. Part 6: N-acyloxymethyl- and N-[(aminocarbonyloxy)methyl]sulfonamides as prodrugs of agents containing a secondary sulfonamide group. Bioorg. Med. Chem. 2000; 8(4): 707-16.
Ludovici, et al. Evolution of anti-HIV candidates. Part 3: Diarylpyrimidine (DAPY) analogues. Bioorg. Med. Chem. Lett. 2001; 11(17): 2235-9.
Olesen, P. The use of bioisosteric groups in lead optimization. Current Opinion in Drug Discovery & Development. 2001; 4: 471-78.
Patani, et al. Bioisosterism: A rational approach in drug design. Chem. Rev. 1996; 96(8): 3147-76.
Platt, et al. Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J. Virol. 1998; 72(4): 2855-64.
Popik, et al. Human immunodeficiency virus type 1 uses lipid raft-colocalized CD4 and chemokine receptors for productive entry into CD4(+) T cells. J. Virol. 2002; 76(10): 4709-22.
Poste, et al. Lipid Vesicles as Carriers for Introducing Biologically Active materials into Cells. Methods Cell Biol. 1976;14: 33-71.
Roos, et al. LuSIV cells: A reporter cell line for the detection and quantitation of a single cycle of HIV and SIV replication. Virology. 2000; 273(2): 307-15.
Scott, et al. A new route to the imidazole-2-thiones from 2-thiohydantoins. Implications in the study of ergothioneine. Biochem J. 1968; 109(2):209-15.
Seela, et al. Synthesis of 2′-deoxyribofuranosides of 8-aza-7-deazaguanine and related pyrazolo[3,4-d]pyrimidines. Helvitica Chimica Acta. 1986; 69(7): 1602-13.
Seela, et al. The high-anti conformation of 7-halogenated 8-aza-7-deaza-2′-deoxy-guanosines: A study of the influence of modified bases on the sugar structure of nucleosides. Helvitica Chimica Acta. 1999; 82(1): 105-24.
Taylor, et al. Synthesis of pyrazolo[3,4-d]pyrimidine analogues of the potent antitumor agent N-{4-[2-amino-4(3H)-oxo-7H-pyrrolo[2,3-d]pyrimidin-5-y1)ethyl]benzoyl}-L-glutamic acid (LY231514). Tetrahedron. 1992; 48(37): 8089-100.
Youssif, et al. A Facile One-pot Synthesis of Fused 2-Thiouracils: Dipyrimidinopyridine, Pyrazolopyrimidine and Pyridazinopyrimidines. Bull. Kor. Chem. Soc. 2003; 24: 1429-32.
PCT/US03/27433 International Search Report dated Mar. 26, 2004.
PCT/US03/27433 International Preliminary Examination Report dated Jun. 14, 2004.
PCT/US05/30259 International Preliminary Report on Patentability dated Feb. 28, 2007.
PCT/US05/39294 International Preliminary Report on Patentability dated Apr. 29, 2008.
EP03786506 Supplementary Search Report dated Feb. 2, 2009.
Ep 05790722 Search Opinion dated Jul. 3, 2009.
Ep 09170772 Search Opinion dated Nov. 9, 2009.
PCT/US09/61969 Search Report dated Feb. 4, 2010.
PCT/US09/61970 Search Report dated Feb. 4, 2010.

Affiliated with

Also associated with

Rating

S-triazolyl α-mercaptoacetanilides as inhibitors of... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with S-triazolyl α-mercaptoacetanilides as inhibitors of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and S-triazolyl α-mercaptoacetanilides as inhibitors of... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2622410